Aldeyra Therapeutics, Inc. — Form 8-K
Filed September 29, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 58/100
What the filing says
Aldeyra Therapeutics announced intent to submit a Formal Dispute Resolution Request (FDRR) to the FDA's Office of New Drugs on September 29, 2026, appealing three Complete Response Letters rejecting reproxalap for dry eye disease. The company submitted nine clinical trials across three NDA resubmissions; five trials met all primary endpoints. Aldeyra holds $45.1M cash (as of June 30, 2026) and projects runway into 2029; an FDA OND meeting is expected Q4 2026, though the FDRR timeline and outcome remain uncertain.
Why this rating
FDRR is a meaningful but uncertain regulatory recourse (not a new development), representing ~20% of company's market cap in at-stake value; outcome highly uncertain and procedurally unpredictable; moderate consequence for a ~$230M company.
See more from September 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.